Agile Therapeutics, Inc. (AGRX)
| Market Cap | 93.93M |
| Revenue (ttm) | 2.05M |
| Net Income (ttm) | -67.91M |
| Shares Out | 88.69M |
| EPS (ttm) | -0.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 369,637 |
| Open | 1.02 |
| Previous Close | 1.01 |
| Day's Range | 1.01 - 1.04 |
| 52-Week Range | 0.93 - 3.77 |
| Beta | 0.96 |
| Analysts | Buy |
| Price Target | 3.83 (+268.3%) |
| Est. Earnings Date | Nov 4, 2021 |
About AGRX
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a reg...
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for AGRX stock is "Buy." The 12-month stock price forecast is 3.83, which is an increase of 268.27% from the latest price.
News
Agile Therapeutics to Participate in Upcoming Investor Conferences
PRINCETON, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that management will present and participate at the following v...
Agile Therapeutics Partners with Telehealth Service, Pandia Health, to Increase Women's Access to Twirla® (levonorges...
PRINCETON, N.J., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced a partnership with Pandia Health, an online telehealth service, ...
2 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overa...
3 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overa...
Agile Therapeutics (AGRX) Reports Q2 Loss, Lags Revenue Estimates
Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 4.76% and -18.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Agile Therapeutics: Q2 Earnings Insights
Shares of Agile Therapeutics (NASDAQ:AGRX) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 66.67% year over year to ($0.20), which beat the ...
Agile Therapeutics Reports Second Quarter 2021 Financial Results
Total Prescriptions (TRx) Grew 171% in Second Quarter
Agile Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on Monday, July 26, 2021
Live Conference Call and Webcast at 4:30 p.m. EDT Live Conference Call and Webcast at 4:30 p.m. EDT
Agile Therapeutics to Participate in the William Blair 41st Annual Growth Stock Conference
PRINCETON, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the company will be participating virtually in the William Blair ...
Agile Therapeutics (AGRX) Reports Q1 Loss, Lags Revenue Estimates
Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 9.09% and -82.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Agile Therapeutics Q1 Earnings
Shares of Agile Therapeutics (NASDAQ:AGRX) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 100.00% year over year to ($0.20), which bea...
Agile Therapeutics Reports First Quarter 2021 Financial Results
Prescription Growth Reflects Increasing Demand for Twirla
Agile Therapeutics Announces Presentation of Safety and Efficacy Data of Twirla® (Levonorgestrel and Ethinyl Estradio...
PRINCETON, N.J., April 30, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that a post hoc analysis of the Phase 3 SECURE Trial evaluating...
CORRECTING AND REPLACING -- Agile Therapeutics
PRINCETON, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by Agile Therapeutics, Inc. (Nasdaq: AGRX), please note the headline should read "Agile Therapeutics to Report First...
Agile Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on Tuesday, May 4, 2020
Live Conference Call and Webcast at 4:30 p.m. EDT Live Conference Call and Webcast at 4:30 p.m. EDT
Agile Therapeutics to Present at Upcoming March Investor Conferences
PRINCETON, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will pres...
Agile Therapeutics (AGRX) Reports Q4 Loss, Misses Revenue Estimates
Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 13.04% and -25.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Agile Therapeutics Reports Fourth Quarter & Full Year 2020 Financial Results; Expands Loan Facility With Perceptive A...
Perceptive Advisors Increases Credit Facility to $45 million, with $25 million potentially available
Agile Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Provide Corporate ...
Live Conference Call and Webcast at 4:30 p.m. ET
Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
PRINCETON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced Chairman and Chief Executive Officer Al Altomari will participat...
Agile Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the Company will present at the 39th Annual J.P. Morgan Healthca...
Agile Therapeutics: Managing A Position Ahead Of Twirla's Launch
Agile Therapeutics is preparing to launch their first FDA approved product, Twirla. If all goes well, Twirla could quickly establish a foothold in a $4.1B addressable market. Launching an FDA approved p...
Agile Therapeutics Announces Nationwide Commercial Launch and Availability of Twirla® (levonorgestrel and ethinyl est...
Once-Weekly Twirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE)